Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$1.51 USD
+0.04 (2.72%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $1.47 -0.04 (-2.65%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Barinthus Biotherapeutics PLC Sponsored ADR [BRNS]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Barinthus Biotherapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Strategic Pipeline Prioritization; Reiterate Buy; Adjusting PT to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Barinthus Biotherapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
VTP-300 Achieves Undetectable HBsAg Levels in Chronic Hepatitis B; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Barinthus Biotherapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Barinthus Biotherapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Barinthus Biotherapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
2023 Financial Results Reported; Reiterate Buy; Lowering PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Barinthus Biotherapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Multiple Data Readouts Expected in 1H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Barinthus Biotherapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
New Partnership Inked on Vaccine Against MERS-CoV; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Barinthus Biotherapeutics PLC Sponsored ADR
Industry: Medical - Biomedical and Genetics
Promising Interim Data from HBV Trials Presented; 3Q23 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
|